

Joint Investigation of Two-Month Post-Diagnosis IgG Antibody Levels and Psychological Measures for Assessing Longer Term Multi-Faceted Recovery among COVID-19 Cases in Northern Cyprus

Burç Barın^{1*}, Banu E. Yoldascan², Fatma Savaskan³, Goncagül Özbalıkcı⁴, Tuğçe Karaderi⁵, Huseyin Çakal⁶

¹The Emmes Company, United States, ²Department of Public Health, Faculty of Medicine, Cyprus International University, Cyprus, ³Infection Control Unit, Burhan Nalbantoglu State Hospital, Cyprus, ⁴Microbiology Laboratory, Burhan Nalbantoglu State Hospital, Cyprus, ⁵Disease Systems Biology Program, Novo Nordisk Foundation Center for Protein Research, Faculty of Medical and Health Sciences, University of Copenhagen, Denmark, ⁶School of Psychology, Keele University, United Kingdom

Submitted to Journal:
Frontiers in Public Health

Specialty Section:
Infectious Diseases - Surveillance, Prevention and Treatment

Article type:
Brief Research Report Article

Manuscript ID:
590096

Received on:
31 Jul 2020

Revised on:
19 Oct 2020

Frontiers website link:
www.frontiersin.org

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest

Author contribution statement

Elcin Yoldascan, Burc Barin, Fatma Savaskan planned the study and its implementation.

Burc Barin, Huseyin Cakal, Elcin Yoldascan and Fatma Savaskan designed the psychological survey.

Fatma Savaskan coordinated the fieldwork for collection of blood samples, administration of psychological surveys and compilation of survey data.

Goncagul Ozbalkici coordinated processing of blood samples, running of immunoassays and compilation of the assay data.

Burc Barin and Huseyin Cakal performed the statistical analyses.

Burc Barin wrote the first draft.

Tugce Karaderi and Huseyin Cakal conducted critical review/editing for the major revision.

Burc Barin, Tugce Karaderi, Huseyin Cakal conceptualized, revised and finalized the article.

All authors have reviewed the article, provided feedback and approved the article for publication.

Keywords

COVID-19, SARS-CoV-2, Recovery, immune response, antibody, Psychological impact, Trauma, stigma

Abstract

Word count: 250

Following the outbreak of COVID-19, multidisciplinary research focusing on the long-term effects of the COVID-19 infection and the complete recovery is still scarce. With regards to long-term consequences, biomarkers of physiological effects as well as the psychological experiences are of significant importance for comprehensively understanding the complete COVID-19 recovery period. The present research surveys the IgG antibody titers and the impact of COVID-19 as a traumatic experience in the aftermath of the active infection period, around two months after diagnosis, in a subset of COVID-19 patients from the first wave (March-April 2020) of the outbreak in Northern Cyprus. Associations of antibody titers and psychological survey measures with baseline characteristics and disease severity were explored, and correlations among various measures were evaluated. Of the 47 serology tests conducted for presence of IgG antibodies, 39 (83%) were positive. We identified trends demonstrating individuals experiencing severe or critical COVID-19 disease and/or those with comorbidities are more heavily impacted both physiologically and mentally, with higher IgG titers and negative psychological experience compared to those with milder disease and without comorbidities. We also observed that more than half of the COVID-19 cases had negative psychological experiences, being subjected to discrimination and verbal harassment/insult, by family/friends. In summary, as the first study co-evaluating immune response together with mental status in COVID-19, our findings suggest that further multidisciplinary research in larger sample populations as well as community intervention plans are needed to holistically address the physiological and psychological effects of COVID-19 among the cases in the long-term.

Contribution to the field

Our study is important as it is the first study jointly evaluating post-discharge blood antibody levels and psychological status of COVID-19 cases at a median time of two months after diagnosis. Severe/critical COVID-19 cases had higher blood IgG antibody levels as well as the highest long-term mental impact. Holistic and a more personalized approach is needed for post-discharge monitoring and treatment of COVID-19 cases, with a focus on older age, comorbidity status and disease severity.

Ethics statements

Studies involving animal subjects

Generated Statement: No animal studies are presented in this manuscript.

Studies involving human subjects

Generated Statement: The studies involving human participants were reviewed and approved by The study has been reviewed and approved by the International Cyprus University Ethics Committee in Nicosia, Cyprus. . Written informed consent to participate in this study was provided by the participants' legal guardian/next of kin.

Inclusion of identifiable human data

Generated Statement: No potentially identifiable human images or data is presented in this study.

In review

Data availability statement

Generated Statement: The raw data supporting the conclusions of this article will be made available by the authors, without undue reservation.

In review

1 | **Joint Investigation of Two-Month Post-Diagnosis IgG Antibody Levels and**
2 | **Psychological Measures for Assessing Longer Term Multi-Faceted Recovery among**
3 | **COVID-19 Cases in Northern Cyprus**

4 |
5 | **Authors:**

6 | Burc Barin*, Banu Elcin Yoldascan, Fatma Savaskan, Goncagul Ozbalkici, Tugce
7 | Karaderi**, Hüseyin Çakal**.

8 | * corresponding author

9 | ** co-senior authors

10 |
11 | **Abstract:**

12 | Following the outbreak of COVID-19, multidisciplinary research focusing on the long-
13 | term effects of the COVID-19 infection and the complete recovery is still scarce. With
14 | regards to long-term consequences, biomarkers of physiological effects as well as the
15 | psychological experiences are of significant importance for comprehensively
16 | understanding the complete COVID-19 recovery. The present research surveys the IgG
17 | antibody titers and the impact of COVID-19 as a traumatic experience in the aftermath of
18 | the active infection period, around two months after diagnosis in a subset of COVID-19
19 | patients from the first wave (March-April 2020) of the outbreak in Northern Cyprus.
20 | Associations of antibody titers and psychological survey measures with baseline
21 | characteristics and disease severity were explored, and correlations among various
22 | measures were evaluated. Of the 47 serology tests conducted for presence of IgG
23 | antibodies, 39 (83%) were positive. We identified trends demonstrating individuals
24 | experiencing severe or critical COVID-19 disease and/or those with comorbidities are
25 | more heavily impacted both physiologically and mentally, with higher IgG titers and
26 | negative psychological experience compared to those with milder disease and without
27 | comorbidities. We also observed that more than half of the COVID-19 cases had negative
28 | psychological experiences, being subjected to discrimination and verbal
29 | harassment/insult, by family/friends. In summary, as the first study co-evaluating
30 | immune response together with mental status in COVID-19, our findings suggest that
31 | further multidisciplinary research in larger sample populations as well as community
32 | intervention plans are needed to holistically address the physiological and psychological
33 | effects of COVID-19 among the cases.

34 | **Keywords:** COVID-19, SARS-CoV-2, recovery, immune response, antibody,
35 | psychological impact, trauma, stigma.

36 |
37 |
38 | **Section I. Introduction**

39 |
40 | Coronavirus disease of 2019 (COVID-19), resulting from SARS-CoV-2 infection, was
41 | declared a pandemic by the World Health Organization on 11 March 2020. As of 29 July
42 | 2020, more than 16,000,000 COVID-19 cases were identified, and more than 650,000
43 | deaths were reported due to the disease (1). Although the scientific community has
44 | responded rapidly to detect the transmission mechanisms and develop vaccines,
45 | multidisciplinary research focusing on the long-term effects of the COVID-19 infection is
46 | still scarce, and not much is known on how the human body responds to COVID-19

Burc 9/27/20 11:35 AM

Comment [1]: Corrected error from first version.

Burc 8/27/20 1:14 PM

Deleted: Discharge

Burc 9/27/20 11:34 AM

Comment [2]: Revised per Comment by Reviewer #1.

Burc 9/27/20 10:59 PM

Deleted: ‘

Burc 9/27/20 11:34 AM

Deleted: longer term

Burc 9/27/20 10:59 PM

Deleted: ‘

Burc 9/27/20 10:59 PM

Deleted: whole

Burc 9/27/20 11:00 PM

Deleted: period

Burc 9/27/20 11:36 AM

Comment [3]: Corrected error from the first version.

Burc 8/27/20 1:14 PM

Deleted: discharge

Burc 9/27/20 12:00 PM

Comment [4]: Added in per Comment by Reviewer #1.

Burc 9/27/20 11:44 AM

Comment [5]: Clarified per Comment by Reviewer #1.

Burc 9/27/20 11:44 AM

Comment [6]: Removed “long-term” per the Comment by Reviewer #1.

Burc 9/27/20 11:43 AM

Deleted: in the long-term

55 infection, both biologically and psychologically during the ‘longer term recovery’ period
56 after discharge from the hospital/isolation. With regards to long-term effects, biomarkers
57 of physiological effects as well as the psychological experiences are of significant
58 importance for a comprehensive understanding of the COVID-19 recovery period (2).
59 COVID-19 as a life-threatening infection can act as an acute stressor (3) and stress can
60 have a down-regulatory effect on the immune system (4). The present research surveys
61 the IgG antibody titers and the impact of COVID-19 as a traumatic experience both
62 during and in the aftermath of the active infection period.

63
64 There is insufficient information on the immune response to COVID-19 (e.g. prevalence
65 of different antibodies against the infection over time and development of long-term
66 immunity). It is essential to better understand the timeline of immune response including
67 the appearance of immunoglobulin M (IgM) and immunoglobulin G (IgG) antibodies,
68 their lifespan and whether they are protective, at least partially, against a second
69 infection. Preliminary research shows that detectable IgG antibodies generally start
70 appearing after the first week after symptom onset, reach a peak around two to three
71 weeks, and stay at detectable blood levels at least for a duration of 2-3 months even in
72 milder cases, similar to previous observations in other SARS infections (5-7). Moreover,
73 the psychological effects of having the infection are also complex. The potential life-
74 threatening impact, of having severe COVID-19, the overall disease burden, along with
75 many unknowns about its short- and long-term effects, increase the stigma attached to the
76 infection and the related anxiety among the public. These factors, in turn, make COVID-
77 19 cases more vulnerable to post-traumatic stress as well as targets for harassment and
78 discrimination (8). It is presumed that the period of complete physiological and
79 psychological recovery from the infection depends on disease severity and other
80 physiological and socioeconomic factors. However, given all the elaborate aspects of
81 COVID-19 yet to be investigated and understood, the multi-faceted complete recovery
82 period is still far from being deciphered.

83
84 From a psychological point of view, initial findings suggest that both the disease itself
85 and the negative consequences of the lockdown imposed by governments to curb the
86 spread of the disease could result in negative coping behaviour which includes but is not
87 limited to panic, anxiety, stigmatization, and post-traumatic stress disorder (PTSD) (3).
88 As scarce research shows, these reactions can also be influenced by contextual factors
89 such as a history of war, famine, natural disasters, man-made accidents and the size of the
90 population. More specifically, while smaller nations might appear to have the upper hand
91 in rapid enforcement of measures, contextual factors such as the increased connectivity of
92 the individuals in smaller societies, or negative collective experiences of war and famine
93 in the past might increase the prevalence of negative coping behaviours and stigma
94 induced depression (9).

95
96 A particular case in point is Northern Cyprus, governed by a state that remains
97 internationally unrecognized, and hence, not included in the global epidemiological
98 COVID-19 statistics. In the first wave of the COVID-19 outbreak in Northern Cyprus,
99 108 cases were diagnosed between 10 March and 16 April 2020. The authorities
100 responded promptly and lockdown was imposed on March 11 (9) effectively halting

Burc 9/27/20 12:02 PM
Comment [7]: To address question by Reviewer #1: Correct, ‘discharge’ in our analysis refers to either discharge from hospital or isolation – this has been further defined/clarified in the methods section.

Burc 10/17/20 3:44 PM
Deleted:

Burc 9/27/20 12:12 PM
Deleted: risk

Burc 9/27/20 12:08 PM
Deleted: ,

Burc 9/27/20 12:13 PM
Deleted: and

Burc 9/27/20 12:14 PM
Comment [8]: Clarified and split the sentence into two parts per Comment by Reviewer #1.

Burc 9/27/20 12:05 PM
Comment [9]: Revised per comment by Reviewer #1.

Burc 9/27/20 12:05 PM
Deleted: long-term

Burc 9/27/20 12:16 PM
Comment [10]: Added in per Comment by Reviewer #1.

106 education and government offices, and all other services except those considered
 107 essential. In addition to the global concern over the pandemic, the small community
 108 setting in Northern Cyprus (an estimated total population of around 400,000) with a
 109 history of war and trauma (10) further caused intensified anxiety and fear in an already
 110 sensitive population. Panic engulfed the small nation and there was widespread stigma
 111 toward those who tested positive or considered high-risk for transmitting the disease, i.e.
 112 Turkish Cypriots living abroad, who were brought home and quarantined (11). Videos of
 113 individuals under duress as a result of being quarantined were widely circulated in the
 114 social media, and there were news of occasional small-scale protests in neighbourhoods
 115 where quarantine hotels were chosen due to the perceived infection threat (12). Similarly,
 116 those who were tested positive recounted psychological trauma as their names made
 117 public and have been targeted (13). Therefore, there is sufficient grounds to assume that
 118 in addition to the physiological impact of the disease, those who tested positive for the
 119 COVID-19 have also experienced psychological distress during and after the active
 120 infection period. In fact, in an earlier study conducted in Wuhan (China), the prevalence
 121 of significant post-traumatic stress symptoms associated with COVID-19 was estimated
 122 as 96.2% among clinically stable COVID-19 cases at discharge from quarantine (14).
 123 Taken together, these observations suggest that assessing the biological markers of
 124 physiological effects vis-à-vis negative psychological experiences of the COVID-19
 125 cases is important for holistic management of COVID-19 patients from diagnosis to
 126 potentially complete physiological and psychological recovery. The present research
 127 surveys the immune response (IgG antibody titers) and negative psychological
 128 experiences among the COVID-19 cases in the complete recovery period in the small
 129 society setting of Northern Cyprus.

132 Section II. Sample Population and Methodology

134 Participants and Study Design

135 We performed a joint investigation of the immune response and mental status of the
 136 COVID-19 cases at an average time of two months after diagnosis. Within the scope of
 137 our study, these two main outcomes of interest comprise the assessments toward the
 138 complete recovery of the cases. Of the 108 cases diagnosed, 32 were tourists on the
 139 island: two died with the disease, and the remaining 30 individuals returned to their
 140 country after discharge from hospital/isolation. Dependent on the severity of the disease,
 141 COVID-19 cases were either monitored in the hospital or isolation hotels designated by
 142 the health authority. Of the remaining 76 individuals residing in Northern Cyprus, two
 143 died with the disease. A total of 74 individuals were invited to participate in the post-
 144 discharge assessment of antibody development and psychological impact. For the
 145 psychological evaluation, eight individuals under the age of 18 as well as three
 146 individuals who did not speak Turkish or English fluently were excluded from the study.
 147 Hence, a total of sixty-three individuals were eligible to participate in the psychological
 148 evaluation.
 149

- Burc 10/2/20 11:17 PM
Deleted: scare about
- Burc 10/2/20 11:22 PM
Deleted: an
- Burc 10/2/20 11:21 PM
Deleted: disease stigm
- Burc 10/2/20 11:21 PM
Deleted: a. On the one hand, p
- Burc 10/2/20 11:29 PM
Deleted: On the other hand, v
- Burc 10/2/20 11:36 PM
Comment [11]: Revised these sentences to flow better per comments by Reviewer #1.
- Burc 10/2/20 11:30 PM
Deleted: the public reacted negatively
- Burc 10/17/20 3:45 PM
Deleted:
- Burc 9/28/20 2:10 AM
Deleted: ... [1]
- Burc 10/17/20 3:59 PM
Comment [12]: Revised to a consistent terminology per comment by Reviewer #1.
- Burc 10/17/20 3:57 PM
Deleted: extended
- Burc 9/27/20 11:47 AM
Comment [13]: Corrected the error in the first version.
- Burc 8/27/20 1:15 PM
Deleted: discharge from the hospital/isolation
- Burc 10/17/20 3:46 PM
Deleted: T
- Burc 10/17/20 3:59 PM
Deleted: longer term
- Burc 9/27/20 11:56 AM
Comment [14]: Per Comment by Reviewer #1, we further defined in this sentence what 'discharge' refers to in the regional context.
- Burc 9/27/20 12:39 PM
Comment [15]: Clarified per Comment by Reviewer #1.
- Burc 9/27/20 12:39 PM
Deleted: /

165 All subjects were informed about both components of the study, provided informed
166 consent acknowledging voluntary participation, option to withdraw from study at any
167 time, and the confidentiality of their antibody results and their responses to the survey.

168

169 Eligibility Criteria

170 *General Inclusion Criteria:* Confirmed (i.e., with positive polymerase chain reaction test
171 result) COVID-19 infection in Northern Cyprus between the dates of 10 March – 17
172 April and residence in northern Cyprus.

173 *Exclusion Criteria for Antibody Development Analysis:* Refusal to give informed consent,
174 or contraindication to venipuncture.

175 *Exclusion Criteria for Psychological Survey:* Refusal to give informed consent, inability
176 to understand/speak Turkish or English fluently, or being under the age of 18.

177

178 Blood Collection and Transfer

179 Blood samples were taken by trained nurses during home visits. Venipuncture was used
180 to collect blood. 10ml complete gel barrier formation tubes were used for blood
181 collection (See Supplementary Text for the details).

182

183 Serology Testing

184 The Abbott SARS-CoV-2 IgG assay is a chemiluminescent microparticle immunoassay
185 (CMIA) intended for both the quantitative and qualitative detection of IgG antibodies to
186 the nucleocapsid protein of SARS-CoV-2 in human blood serum and plasma. Assay
187 specifications indicate that the SARS-CoV-2 IgG assay is intended for use as an aid in
188 identifying individuals with an adaptive immune response to SARS-CoV-2, indicating
189 recent or prior infection. This assay is only for use under the United States Food and
190 Drug Administration's Emergency Use Authorization. Per the assay's recommended
191 definition, we defined positive IgG response in the study as a titer level ≥ 1.4 index
192 signal/cutoff (s/co) (15). Assays were run on Abbott's ARCHITECTplus i2000_{SR} System.

193

194 The reported positive predictive agreement (PPA) for the assay at ≥ 14 days post-
195 symptom onset was 100.0% (95% confidence-interval (CI): 95.9%-100%) while the
196 negative predictive agreement (NPA) was 99.6% (95% CI: 99.1%-99.9%). Performance
197 characteristics of the assay were independently evaluated in a study conducted in Boise,
198 Idaho, where specificity and sensitivity were reported as 99.90% and 100% (starting at
199 day 17 after symptom onset), respectively (16).

200

201 Psychological Measures

202 We designed a questionnaire-based survey to assess the negative psychological
203 experiences of the cases. Whenever possible, we adapted and used tested and validated
204 measures for known psychological processes. More specifically, we assessed the extent
205 of experiencing COVID-19 as a life changing trauma (CALCT), negative emotions,
206 perceived importance of preventive measures, awareness and habits, initial reaction to
207 diagnosis, evaluation of general health, stigma, perceived discrimination, post-traumatic
208 anxiety, and evolving perspectives after discharge via the survey response measures.
209 Ordinal response scales with five levels (with corresponding scores of 1-5) were used for
210 each measure. Multiple measures on the same psychological process were combined to

Burc 9/27/20 12:41 PM

Comment [16]: Reviewer #1 inquired about location of Supplementary Text. This was uploaded separately at the time of submission, along with Supplementary Tables/Figures.

Burc 9/27/20 12:42 PM

Comment [17]: Added in per Comment by Reviewer #1.

Burc 10/20/20 1:20 AM

Comment [18]: Revised per Comment by Reviewer #1.

Burc 10/3/20 1:36 AM

Deleted: already

Burc 10/3/20 12:20 AM

Deleted: to assess the negative psychological experiences of the cases

Burc 9/27/20 12:52 PM

Comment [19]: Moved up the introduction of the abbreviation per Comment by Reviewer #1.

Burc 10/3/20 1:53 AM

Deleted: question

215 | create one composite scale process measure by computing the average score per
216 | individual. Higher computed scores indicated stronger experience of COVID-19 as a life
217 | changing trauma, perceived higher importance of preventive measures, stronger initial
218 | reaction to diagnosis, more positive evaluation of general health, more perceived
219 | discrimination, higher post-traumatic anxiety, and stronger anticipation of future COVID-
220 | 19 related anxiety.

Burc 10/3/20 2:19 AM

Deleted: values

222 | We verified the internal reliability of our multi-item process measures via Chronbach's
223 | alpha ($\alpha > 0.70$). Experiencing COVID-19 as a life-changing traumatic was measured with
224 | three items ($\alpha = 0.84$) adapted from (17). Negative emotions during the recovery were
225 | assessed by four items ($\alpha = 0.79$). Perceived discrimination on the basis of being COVID-
226 | 19 positive was measured by six items ($\alpha = 0.90$) adapted from (18). We also measured
227 | anxiety related to anticipated stigma in the future as a result of COVID-19 diagnosis with
228 | two items ($r = 0.82$, $p < 0.001$). We measured subjective evaluation of health before the
229 | diagnosis and after the discharge with a single item each. Willingness to help others by
230 | sharing information was measured by a single item and perceived importance of
231 | protective measures by 4 items ($\alpha = 0.96$). Full list of the items can be found in the
232 | Supplementary Material - Psychological Survey.

Burc 10/3/20 2:19 AM

Deleted: assessed

Burc 10/3/20 1:58 AM

Deleted: ; See Supplementary Material - Psychological Survey for the full Questionnaire

233 | **Statistical Analysis**

235 | Analysis of quantitative IgG titers and CALCT psychological process scores was
236 | conducted via non-parametric tests: Wilcoxon rank-sum test (for factors with two levels)
237 | and Kruskal-Wallis test (for factors with three or more levels). Due to small group
238 | sample sizes, these rank-based non-parametric tests that do not make any assumptions
239 | regarding the underlying distribution of the data were preferred for group comparisons
240 | (19-20). We computed descriptive statistics for the socio-demographics factors and
241 | summary measures (mean score (M) with standard deviation (SD)) for psychological
242 | processes, and conducted Pearson correlation tests to explore whether the selected
243 | psychological processes were associated with each other. All single-item survey
244 | questions and multi-item process measures use 5-point Likert scales (1 lowest, 5 highest)
245 | and have a mid-level at 2.5. Disease severity was defined as critical (requiring intensive
246 | care), severe (requiring oxygen therapy, but otherwise stable) and mild/moderate (all
247 | other cases). P-values less than 0.001 were displayed as " $p < 0.001$ ". Statistical
248 | significance was defined as $p < 0.05$. Multivariate analyses were not carried out due to
249 | small sample size. Analyses were performed using SAS version 9.4 (SAS, Cary, NC,
250 | USA).

Burc 10/20/20 1:21 AM

Comment [20]: We have re-written the Psychological Processes section to more clearly define the computation of the derived process scores and to make the flow better/clearer in order to address Comment by Reviewer #2.

Burc 10/19/20 10:38 PM

Comment [21]: To address a comment by Reviewer #2, we added further clarification and references on the statistical tests used for group comparisons.

Burc 10/19/20 10:36 PM

Formatted: Font color: Red

Burc 10/19/20 10:36 PM

Formatted: Font color: Red

Burc 10/4/20 8:38 AM

Deleted: and

Burc 10/4/20 8:37 AM

Deleted: single items

Burc 10/4/20 8:46 AM

Formatted: English (US)

252 | **Section III. Results**

254 | **Baseline Characteristics**

255 | Of the 74 cases eligible for serology testing, 47 (64%; 60% women and 40% men)
256 | accepted the invite and provided blood for testing. Median [interquartile range (IQR)]
257 | time from initial COVID-19 diagnosis to blood draw for serology testing was 66 [63.5-
258 | 73] days with min-max of 50-86 days. Of the 63 cases eligible for responding to the
259 | psychological survey, 41 (65%) responded to survey questions (Table 1).

Burc 9/27/20 12:48 PM

Comment [22]: Corrected an error from the first version.

Burc 8/27/20 1:18 PM

Deleted: 4

260 | For the serology testing, 19% were <30 years of age, 53% were between 30-60 years old,

269 and 28% were ≥ 60 years of age. At the time of COVID-19 diagnosis, 79% and 47% of
270 the serology analysis participants reported 'at least one symptom' and 'fever history',
271 respectively. Thirty-two percent had at least one comorbidity – most frequently
272 hypertension (N=9) and diabetes (N=5, two with concurrent hypertension). COVID-19
273 disease severity was severe or critical for 9 (19%) cases and mild/moderate for the
274 remaining 38 (81%). For the psychological survey, distributions of participant baseline
275 and disease severity characteristics were similar to those of the blood serology analysis
276 (**Table 1**). Detailed cross-tabulation of baseline characteristics and disease severity by
277 age group is displayed in **Supplementary Table 1**.

278 **Serology**

279 Of the 47 serology tests conducted for IgG antibody development, 39 (83%) were
280 positive and 8 (17%) were negative. All of the negative results came from individuals
281 who experienced mild/moderate disease. Overall median [IQR] titer level was 4.38 [2.05-
282 5.88]. Median [IQR] titer level among positives and negatives were 4.95 [3.79-6.09] and
283 0.61 [0.16-0.72], respectively.

284
285 **Figure 1** and **Supplementary Table 2** display the distribution of IgG antibody titers by
286 baseline characteristics and disease severity. The factor that had the most impact on IgG
287 titer at a median follow-up of two months post-diagnosis was disease severity. Nine
288 subjects who had severe/critical disease had median [IQR] IgG titer of 6.09 [5.88-6.24]
289 versus 3.94 [1.70-5.52] reported for thirty-eight subjects with mild/moderate disease
290 (Wilcoxon rank-sum test; $p=0.001$). Among the baseline factors, fever/history of fever
291 reported at the time of diagnosis yielded median [IQR] IgG titer of 5.56 [4.11-6.20]
292 versus 3.57 [1.47-5.13] reported for those without fever/history of fever (Wilcoxon rank-
293 sum test; $p=0.01$). Having a comorbidity also produced higher median [IQR] IgG titers
294 of 5.52 [4.31-6.09] versus 3.87 [1.25-5.56] in those without a comorbidity (Wilcoxon
295 rank-sum test; $p=0.03$).

296
297 The distributions of IgG titers by cross-tabulation of baseline characteristics and disease
298 severity are displayed in **Supplementary Table 3**. In the mild/moderate disease severity
299 group, a significantly higher level of IgG titer was observed in individuals with
300 comorbidities (median [IQR]: 5.02 [3.92-5.67]) compared to those without (median
301 [IQR]: 3.43 [0.88-4.87]) (Wilcoxon rank-sum test; $p=0.03$).

303 **Negative Psychological Experiences**

304 We report the descriptive statistics and the associations between negative psychological
305 processes in **Table 2**.

306
307 | Perception of COVID-19 diagnosis as a life changing traumatic event revealed a mean
308 score of 3.17 [SD 1.41], which is above the mid-level. **Figure 2** displays the distribution
309 of CALCT scores by baseline characteristics and disease severity. Similar to the IgG titer
310 analysis, the factors that have shown trends for the most impact on CALCT scores at a
311 median follow-up of two months post-diagnosis was disease severity, followed by
312 presence of a comorbidity. Mean (SD) CALCT scores in mild/moderate and
313 severe/critical disease groups were 3.01 (1.38) and 3.95 (1.42), respectively (Wilcoxon
314 rank-sum test; $p=0.10$). For individuals with a comorbidity, mean (SD) CALCT score

Burc 9/27/20 12:50 PM

Deleted: (CALCT)

316 was 3.53 (1.48) as compared to 3.02 (1.39) in those without (Wilcoxon rank-sum test;
317 $p=0.30$).

318

319 Among the individual questions measuring the negative psychological experiences,
320 twenty-four (59%) respondents indicated a change in their perspective on life and their
321 priorities due to the COVID-19 infection. All six (100%) responders to the question with
322 severe/critical disease and 18 out of 33 (55%) responders with mild/moderate disease
323 indicated a change in their perspective on life and their priorities due to the COVID-19
324 infection. 19 (46%) individuals indicated that they have become a more worried/anxious
325 person because of the infection, and 20 (49%) perceived the infection period as a turning
326 point in their lives (42% and 75% of the individuals with mild/moderate and
327 severe/critical disease, respectively) (**Supplementary Table 4**).

328

329 The mean score for the negative emotions due to COVID-19 diagnosis was 2.61 (SD
330 1.25) and also above the mid-level of the scale (2.5). As for the individual emotions, felt
331 as an initial reaction to COVID-19 diagnosis, worry ranked the first with 71% of
332 respondents having felt it moderately, a lot or quite a lot, followed by helplessness (47%),
333 fear of death (31%) and guilt due to not being sufficiently self-protected (19%). Fear of
334 death and helplessness were both reported moderately or above by 27% and 50% of
335 individuals in the mild/moderate and severe/critical disease severity groups, respectively
336 (**Supplementary Table 5**).

337

338 Additional analyses of our psychological measures revealed that perceiving COVID-19
339 as a life changing trauma is strongly and positively associated with experiencing negative
340 emotions ($r=0.54$, $p<0.001$); perceived discrimination ($r=0.54$, $p<0.001$); and future
341 stigma related anxiety ($r=0.54$, $p<0.001$). Similarly, perceived importance of protective
342 measures is again strongly and positively associated with pro-social tendencies ($r=0.41$,
343 $p<0.001$). Last but not least, perceived discrimination at present is strongly and positively
344 associated future stigma related anxiety ($r=0.80$, $p<0.001$) (**Table 2**).

345

346 **Section IV. Conclusions**

347

348 We detected IgG antibodies in 39 (out of 47; 83%) of cases after a median of 66 days,
349 which was a considerably longer follow-up period compared to the previous serological
350 studies on IgG (on average up to ~30 days; [21-23](#)). This observation confirms that IgG
351 antibodies are still detectable in the blood in most COVID-19 cases around 2 months
352 post-diagnosis. However, further studies are necessary to determine the neutralizing
353 activity of these antibodies and whether they provide any immunity against a second
354 infection. Moreover, severe/critical COVID-19 cases most of whom were older and/or
355 with comorbidities had higher IgG titers, and also showed trends for the most impact
356 mentally. Overall, we conclude that more specialized attention should be paid to this
357 group for providing further monitoring and treatment post-discharge because of their
358 higher healthcare needs related to comorbidities as well as the psychological impact in
359 order to expedite the full recovery period after the infection.

360

Burc 10/19/20 10:39 PM

Deleted: 19

Burc 10/19/20 10:39 PM

Deleted: 21

363 Our analyses replicated the previous observations that disease severity is an important
364 predictor of blood IgG levels (21-23), and confirmed that this observation holds true in
365 the longer follow-up period we examined. Furthermore, among individuals with mild or
366 moderate disease, we observed that those with comorbidities had significantly higher IgG
367 levels (Supplementary Table 3). Similarly, Liu *et al.* observed that besides the severe
368 COVID-19 cases who tended to have a more vigorous IgG response, a subset of the cases
369 with mild disease had a robust IgG antibody response, and suggested that age and
370 comorbidities may impact the timing and magnitude of the immune response (23).
371 Fever reported at the time of diagnosis also hinted at a possible association with post-
372 discharge IgG levels, but studies with larger case numbers are needed to evaluate these
373 potential predictors of IgG levels with respect to potential confounders such as age, sex,
374 different types of co-morbidities (e.g. autoimmune and endocrine-related diseases) and
375 disease severity via multivariate models. All these factors with potential association to
376 higher IgG titers are correlated with each other, and reflect increased disease burden
377 during diagnosis and post-discharge (Supplementary Table 1). It is known that severity
378 of COVID-19 is associated with a dysregulated immune response, and hence, further
379 investigation of how dysregulated immune response is reflected in the long-term blood
380 antibody levels may provide insights into the biological mechanism of the disease and
381 support development of effective vaccines that are based on long-term immune response
382 (24, 25).

383
384 In line with previous research, one in every two individuals with severe/critical disease
385 felt fear of death and helplessness while one in every four individuals with mild/moderate
386 disease felt these two emotions. Worry was the most commonly expressed emotion
387 among the four negative emotions queried, with 71% of respondents having felt it
388 moderately or more (Supplementary Table 5). Based on the responses to the
389 psychological survey about two months after diagnosis, we infer that most cases have not
390 yet recovered from the mental impact of the disease. Participants experienced COVID-19
391 as a life-changing trauma, experienced negative emotions, perceived themselves as
392 discriminated against and experienced anxiety due to anticipated stigma in the future. In
393 addition to replicating previous research on the negative psychological consequences of
394 being tested positive for an infectious disease and that pandemics have a lasting negative
395 impact on mental health among the general population (26-28), our findings also show
396 that cases experienced anxiety as a result of anticipated stigma. This is a novel finding
397 which reveals that pandemics like COVID-19 have long-term negative mental health
398 effects. Future research could replicate and extend these findings via longitudinal
399 designs.

400
401 Post-traumatic stress is an important part of this disease due to its overall severity, global
402 impact and stigma attached to it. About half of the survey respondents reported being a
403 more worried person due to the infection, and perceiving the infection as a turning point
404 in their life. About one in four individuals also reported concern that their relationship
405 with their workplace and family/friends will deteriorate due to infection. Hence,
406 community resources for provision of psychological support to the COVID-19 cases
407 post-discharge is very important to minimize the long-term impact of the disease and
408 maintain mental health in these individuals. In Northern Cyprus, a number of

Burc 10/19/20 10:39 PM

Deleted: 19

Burc 10/19/20 10:39 PM

Deleted: 21

Burc 10/19/20 10:40 PM

Deleted: 21

Burc 10/19/20 10:40 PM

Deleted: 22

Burc 10/19/20 10:40 PM

Deleted: 23

Burc 10/4/20 10:04 AM

Deleted: five

Burc 10/4/20 10:18 AM

Comment [23]: Clarified reference to worry per a comment by Reviewer #1.

Burc 10/19/20 10:40 PM

Deleted: 24

Burc 10/19/20 10:40 PM

Deleted: 26

417 organizations and universities have already taken action and set up psychological
418 counseling hotlines, free for use by the public (9). These initiatives are very important
419 and need to be expanded throughout the counties, regions and globally. However, more
420 tailored intervention programs are needed especially for COVID-19 cases to combine
421 mental check-ups with regular health check-ups at regular intervals. About one in ten
422 individuals thought they could still transmit the disease. This provides another example
423 of importance of using up-to-date medical info about the disease, and the person's current
424 status in providing tailored therapy to the person for getting over pre-conceived notions
425 about fear of continuing disease in the individual.

426
427 Overall perception about the disease as a threat varied with disease severity
428 (Supplementary Table 12). While more than half of the cases with mild/moderate
429 disease deemed the infection was nothing to be afraid of, only one in four thought the
430 same among the severe/critical cases. Therefore, a consistent public communication
431 strategy is needed to ensure public perception of the disease will not change over time
432 from a conscious alertness to the disease being 'nothing to be afraid of' due to sharing of
433 experiences/perceptions by an estimated 80% of the cases in the mild/moderate severity
434 group among the community.

435
436 The study is subject to a number of limitations. Although our study participation rates of
437 64% (serology) and 65% (psychology) among discharged COVID-19 cases are
438 acceptable for an exploratory study such as this one, there may be some differences
439 between individuals willing and unwilling to participate in the study, especially with
440 respect to psychological endpoints. Actually, we observed lower participation rates in the
441 study by cases from a rural region that was more severely impacted by the outbreak and
442 had to go under a regional quarantine for an extended time. Disease stigma, continuing
443 worry, suspicion and mistrust likely led to lower participation rates, and these factors are
444 directly related to psychological endpoints studied here. To facilitate a more practical
445 implementation in the field, it was not possible to use a consistent time point for
446 evaluation of the outcomes of interest. Nevertheless, timing of blood draw and survey
447 response showed limited variability around a two-month time point post-diagnosis, with
448 median [IQR] and range time being 66 [63.5-73] and 50-86 days, respectively. Due to
449 limited resources, it was not possible to conduct the study longitudinally via multiple
450 time points to evaluate trends in further detail. There were possibly correlated responses
451 for either or both endpoints as we allowed participation of multiple family or household
452 members in the study. There were eight families that were represented in the study with
453 2-3 members each. Finally, compared to continuous IgG titer measures, categorical
454 nature of the survey responses produced higher variability in calculated psychological
455 process scores, and hence, lower statistical power in detecting any associations with
456 baseline factors and disease severity.

457
458 Another major limitation of our study is absence of any data collection on clinical signs,
459 symptoms or measures that are potentially associated with continuing recovery process.
460 At the time we conducted our study, little was known on the long-term impact of
461 COVID-19 and how it manifested in the cases. In recent months, there has been evolving
462 information regarding numerous defined and undefined conditions associated with

Burc 9/27/20 11:49 AM

Comment [24]: Corrected an error in the first version.

Burc 8/27/20 1:31 PM

Deleted: 4

Burc 9/27/20 11:20 PM

Deleted: .

Burc 9/27/20 11:20 PM

Deleted: T

Burc 10/4/20 9:55 AM

Comment [25]: Added in this limitation per a Comment by Reviewer #2.

466 COVID-19, including long-term organ damage, nervous system damage and immune
467 system dysregulations. The most commonly reported general symptoms post acute
468 COVID-19 have been fatigue and dyspnea, followed by joint pain and chest pain. As part
469 of the organ-specific dysfunction, myocardial injury/inflammation has been detected via
470 increased troponin levels and cardiac magnetic resonance imaging, and pulmonary
471 dysfunction via radiologic abnormalities, decreased diffusion capacity for carbon
472 monoxide and diminished respiratory muscle strength. The most common neurologic
473 symptoms reported have been headache, vertigo, anosmia and ageusia, with encephalitis,
474 seizures, major mood swings and “brain fog” also having been reported (29). A refined
475 and detailed assessment of complete recovery process in future studies should include
476 monitoring for these conditions occurring mostly post-discharge via their associated
477 symptoms, laboratory test results and/or medical imaging findings.

478
479 In conclusion, this is the first study jointly evaluating post-discharge blood antibody
480 levels and psychological status at a median time of two months after diagnosis.
481 Severe/critical COVID-19 cases had higher blood IgG antibody levels as well as the
482 highest long-term mental impact. Holistic and a more personalized approach is needed
483 for post-discharge monitoring and treatment of COVID-19 cases, with a focus on older
484 age, comorbidity status and disease severity. Recognizing the long-term impact of the
485 disease (coined as “long COVID”; 30), collaborating globally to accumulate detailed
486 standardized long-term psychological and physiological data (31) and continuing to re-
487 define and publicize the importance of complete recovery are key in addressing the long-
488 term health consequences of COVID-19 via awareness, monitoring and timely
489 intervention.

490
491
492
493
494
495
496
497
498
499
500
501
502
503
504

505 **Acknowledgements**

506 The authors would like to thank study participants as well as Savas Erdogan, Dr. Sebnem
507 Benar, Safiye Ilgilier, Zeynep Unalan, Cigdem Adatas Sesen, Sumru Ozkan Ezer, Ayse
508 Dogan for helping with the conduct of fieldwork and compilation of study data from
509 psychological surveys, Sedef Kutlu and Serife Can from the microbiology laboratory
510 running the immunoassays, Dr. Selin Özcem, Dr. Zafer Erdoğan, Dr. Nesil Bayraktar,
511 Dr. Emre Vudalı, Dr. Mustafa Akansoy, Dr. Emine Kamiloğlu, Dr. Yağmur Aldağ, Dr.

Burc 10/20/20 12:03 AM

Comment [26]: To address one of the major comments by Reviewer #2, we added this paragraph to acknowledge the evolving info in this area and the importance of future studies to take these and new info into account.

512 Hatice C. Caglayan, Dr. Fatma Canbay and Dr. Derlen O. Rus - the treating physicians
513 who contributed to the baseline characteristics data on study participants, and finally, Dr.
514 Ali Pilli, Dr. Ali Caygur, Dr. Sonuc Buyuk, Dr. Cigdem Caga and Dr. Figen Gulen Ince
515 from the Health Authority in Northern Cyprus for supporting this study.

516
517 **T.K.** was supported by the Novo Nordisk Foundation Center for Protein Research (grant
518 NNF14CC0001).

519
520 **Data Availability Statement**
521 The datasets generated for this study are available upon request to the corresponding
522 author.

523
524 **Ethics Statement**
525 The study has been reviewed and approved by the International Cyprus University Ethics
526 Committee. The COVID-19 cases i.e. the participants provided their written informed
527 consent to participate in this study.

528
529 **Author Contributions**
530 Elcin Yoldascan, Burc Barin, Fatma Savaskan planned the study and its implementation.
531 Burc Barin, Huseyin Cakal, Elcin Yoldascan and Fatma Savaskan designed the
532 psychological survey.
533 Fatma Savaskan coordinated the fieldwork for collection of blood samples,
534 administration of psychological surveys and compilation of survey data.
535 Goncagul Ozbalikci coordinated processing of blood samples, running of immunoassays
536 and compilation of the assay data.
537 Burc Barin and Huseyin Cakal performed the statistical analyses.
538 Burc Barin wrote the first draft.
539 Tugce Karaderi and Huseyin Cakal conducted critical review and editing for the major
540 revisions.
541 Burc Barin, Tugce Karaderi, Huseyin Cakal conceptualized, revised and finalized the
542 article.
543 All authors have reviewed the article, provided feedback and approved the article for
544 publication.

545
546 **Conflict of Interest**
547 The authors declare that the research was conducted in the absence of any commercial or
548 financial relationships that could be construed as a potential conflict of interest.

549
550
551 **References**
552 1. World Health Organization. (2020). Coronavirus disease (COVID-
553 19). [https://www.who.int/emergencies/diseases/novel-coronavirus-2019/situation-](https://www.who.int/emergencies/diseases/novel-coronavirus-2019/situation-reports/)
554 [reports/](https://www.who.int/emergencies/diseases/novel-coronavirus-2019/situation-reports/) [Accessed July 29, 2020].
555 2. Holmes, E. A., Connor, R. C. O., Perry, V. H., Tracey, I., Wessely, S., Arseneault, L.,
556 ... Bullmore, E. (2020). Multidisciplinary research priorities for the COVID-19
557 pandemic : a call for action for mental health science. *Lancet Psychiatry*, 7, 547–

- 558 560. [https://doi.org/10.1016/S2215-0366\(20\)30168-1](https://doi.org/10.1016/S2215-0366(20)30168-1)
- 559 3. Dubey, Souvik & Biswas, Payel & Ghosh, Ritwik & Chatterjee, Subhankar & Dubey,
560 Mahua & Chatterjee, Subham & Lahiri, Durjoy & Lavie, Carl. (2020). Psychosocial
561 impact of COVID-19. *Diabetes and Metabolic Syndrome Clinical Research and*
562 *Reviews*. 14. 779-788. 10.1016/j.dsx.2020.05.035.
- 563 4. Segerstrom, S. C., & Miller, G. E. (2006). Psychological Stress and the Human
564 Immune System: A MetaAnalytic Study of 30 Years of Inquiry. *Psychological*
565 *Bulletin*, 130(4), 601–630. <https://doi.org/doi:10.1037/0033-2909.130.4.601>
- 566 5. Sethuraman N., Jeremiah S.S., Ryo A. (2020). Interpreting Diagnostic Tests for SARS-
567 CoV-2. *JAMA*. 2020; 323(22):2249–2251. doi:10.1001/jama.2020.8259
- 568 6. Hou, H., Wang, T., Zhang, B., Luo, Y., Mao, L., Wang, F., Wu, S. and Sun, Z. (2020),
569 Detection of IgM and IgG antibodies in patients with coronavirus disease 2019.
570 *Clin Transl Immunol*, 9: e1136. doi:10.1002/cti2.1136
- 571 7. Seow, J., Graham, C., Merrick, B., Acors, S., ..., Doores, K.(2020). Longitudinal
572 evaluation and decline of antibody responses in SARS-CoV-2 infection. medrxiv
573 2020.07.09.20148429 [Preprint]. Available at:
574 <https://doi.org/10.1101/2020.07.09.20148429> (Accessed July 29, 2020).
- 575 8. Centers for Disease Control and Prevention. (2020). Coronavirus Disease 2019
576 (COVID-19).[https://www.cdc.gov/coronavirus/2019-ncov/daily-life-](https://www.cdc.gov/coronavirus/2019-ncov/daily-life-coping/reducing-stigma.html)
577 [coping/reducing-stigma.html](https://www.cdc.gov/coronavirus/2019-ncov/daily-life-coping/reducing-stigma.html) [Accessed July 29, 2020].
- 578 9. Volkan, E., & Volkan, E. (2020). Under the COVID-19 Lockdown : Rapid Review
579 About the Unique Case of North Cyprus. *Psychological Trauma: Theory, Research,*
580 *Practice, and Policy*, 12(5), 539–541.
581 <https://doi.org/http://dx.doi.org/10.1037/tra0000809>
- 582 10. Volkan, E., & Hadjmarkou, M. M. (2019). Undivided Trauma in a Divided Cyprus:
583 Modified Emotional Stroop Study. *Psychological Trauma: Theory, Research,*
584 *Practice, and Policy, Advance on*(November 2019).
585 <https://doi.org/10.1037/tra0000527>
- 586 11. Yenidüzen. (2020a). Firat Ataser'e Büyük Tepki. *Yenidüzen*. Retrieved from
587 <http://www.yeniduzen.com/firat-atasere-buyuk-tepki-125200h.htm>
- 588 12. Yenidüzen. (2020b). Yurt Krizi: Öğrenciler Perişan.
589 <Http://Www.Yeniduzen.Com/Yurt-Krizi-Ogrenciler-Perisan-125192h.Htm>.
- 590 13. Demir, D. (2020). Dışlandık, hain ilan edildik. *Yenidüzen*. Retrieved from
591 <http://www.yeniduzen.com/dislandik-hain-ilan-edildik-129610h.htm>
- 592 14. Bo, H-X., Li, W., Yang, Y., Wang, Y., Zhang, Q., Cheung, T., Wu, X., Xiang, Y-T.
593 (2020). Posttraumatic stress symptoms and attitude toward crisis mental health
594 services among clinically stable patients with COVID-19 in China. *Psychological*
595 *Medicine* 1–2. <https://doi.org/10.1017/S0033291720000999>
- 596 15. Abbott ARCHITECT SARS-CoV-2 IgG Instructions for Use. H14806R01. April
597 2020 (<https://www.fda.gov/media/137383/download>)
- 598 16. Bryan, A., Pepper, G., Wener, M.H., et al. (2020). Performance Characteristics of the
599 Abbott Architect SARS-CoV-2 IgG Assay and Seroprevalence in Boise, Idaho. *J*
600 *Clin Microbiol*. 58(8):e00941-20. doi:10.1128/JCM.00941-20
- 601 17. García, F. E., Cova, F., Rincón, P., Vázquez, C., & Páez, D. (2016). Coping,
602 rumination and posttraumatic growth in people affected by an earthquake.
603 *Psicothema*, 28(1), 59–65. <https://doi.org/10.7334/psicothema2015.100>

604 18. Branscombe, N. R., Schmitt, M. T., & Harvey, R. D. (1999). Perceiving pervasive
605 discrimination among African Americans: Implications for group identification and
606 well-being. *Journal of Personality and Social Psychology*, 77, 135–149.
607 <https://doi.org/10.1037/0022-3514.77.1.135>

608 19. Wilcoxon, F. (1945). Individual comparisons by ranking methods. *Biom Bull*,
609 1(6):80–83.

610 20. Kruskal, W.H., Wallis, W.A. (1952). Use of ranks in one-criterion variance
611 analysis. *J. Am. Stat. Assoc.* 47, 583–621 and errata, *ibid.* 48, 907–911.

612 21. Zhang G., Nie S., Zhang Z., Zhang Z. (2020). Longitudinal Change of Severe Acute
613 Respiratory Syndrome Coronavirus 2 Antibodies in Patients with Coronavirus
614 Disease 2019. *The Journal of Infectious Diseases*, Volume 222, 2, 15 July 2020,
615 183–188. <https://doi.org/10.1093/infdis/jiaa229>

616 22. Long, Q., Liu, B., Deng, H. *et al.* (2020). Antibody responses to SARS-CoV-2 in
617 patients with COVID-19. *Nat Med*, 26, 845–848. [https://doi.org/10.1038/s41591-](https://doi.org/10.1038/s41591-020-0897-1)
618 [020-0897-1](https://doi.org/10.1038/s41591-020-0897-1)

619 23. Liu, X., Wang, J., Xu, X., Liao, G., Chen, Y. & Hu, C-H. 2020. Patterns of IgG and
620 IgM antibody response in COVID-19 patients. *Emerging Microbes &*
621 *Infections*. 9:1, 1269-1274. DOI: [10.1080/22221751.2020.1773324](https://doi.org/10.1080/22221751.2020.1773324)

622 24. Qin, C., Zhou, L., Hu, Z., *et al.* 2020. Dysregulation of Immune Response in Patients
623 With Coronavirus 2019 (COVID-19) in Wuhan, China, *Clinical Infectious Diseases*,
624 Volume 71, Issue 15, 1 August 2020, Pages 762–768,
625 <https://doi.org/10.1093/cid/ciaa248>

626 25. Diao, B., Wang, C., Tan, Y., Chen, X., Liu, Y., Ning, L., Chen, L., Li, M., Liu, Y.,
627 Wang, G., Yuan, Z., Feng, Z., Zhang, Y., Wu, Y., & Chen, Y. (2020). Reduction
628 and Functional Exhaustion of T Cells in Patients With Coronavirus Disease 2019
629 (COVID-19). *Frontiers in immunology*, 11, 827.
630 <https://doi.org/10.3389/fimmu.2020.00827>

631 26. Maunder, R., Hunter, J., Vincent, L., Bennett, J., Peladeau, N., Leszcz, M., ...
632 Mazzulli, T. (2003). The immediate psychological and occupational impact of the
633 2003 SARS outbreak in a teaching hospital. *Canadian Medical Association Journal*,
634 168, 1245–1251.

635 27. Serafini, G., Parmigiani, B., Amerio, A., Aguglia, A., Sher, L., & Amore, M. (2020).
636 The psychological impact of COVID-19 on the mental health in the general
637 population. *QJM: An International Journal of Medicine*, 1–7.
638 <https://doi.org/10.1093/qjmed/hcaa201>

639 28. Wu, P., Fang, Y., Guan, Z., Fan, B., Kong, J., Yao, Z., ... Hoven, C. W. (2009). The
640 psychological impact of the SARS epidemic on hospital employees in China:
641 Exposure, risk perception, and altruistic acceptance of risk. *Canadian Journal of*
642 *Psychiatry*, 54, 302–311. <https://doi.org/10.1177/070674370905400504>

643 29. Del Rio, C., Collins, L.F., & Malani, P. (2020). Long-term Health Consequences
644 of COVID-19. *JAMA*. doi:10.1001/jama.2020.19719

645 30. Long COVID: let patients help define long-lasting COVID symptoms. (2020).
646 *Nature*, 586, 170. <https://doi.org/10.1038/d41586-020-02796-2>

647 31. University of Oxford. (2020). Global consortium launches new study into long-term
648 effects of COVID-19. [https://www.ox.ac.uk/news/2020-09-11-global-consortium-](https://www.ox.ac.uk/news/2020-09-11-global-consortium-launches-new-study-long-term-effects-covid-19)
649 [launches-new-study-long-term-effects-covid-19](https://www.ox.ac.uk/news/2020-09-11-global-consortium-launches-new-study-long-term-effects-covid-19) [Accessed October 18, 2020].

Burc 10/19/20 10:49 PM

Deleted: 9

Burc 10/19/20 10:49 PM

Deleted: 0

Burc 10/19/20 10:49 PM

Deleted: 1

Burc 10/19/20 10:49 PM

Deleted: 2

Burc 10/19/20 10:49 PM

Deleted: 3

Burc 10/19/20 10:49 PM

Deleted: 4

Burc 10/19/20 10:49 PM

Deleted: 5

Burc 10/19/20 10:49 PM

Deleted: 6

658
659
660
661
662
663
664
665
666
667
668
669
670
671
672
673
674
675

Figure Legends and Tables

Figure 1 Legend. IgG Levels Overall, by Baseline Factors and Disease Severity. IgG levels were measured at a median [IQR] time of 66 [63.5-73] days from initial COVID-19 diagnosis. See Supplementary Table 2 for detailed summary statistics. Mod=Moderate, Sev=Severe.

Figure 2 Legend. COVID-19 as Life-changing Trauma (CALCT) Scores Overall, by Baseline Factors and Disease Severity. Psychological measures were assessed around 2 months from initial COVID-19 diagnosis. See Supplementary Table 4 for distribution of responses to the three CALCT survey items. Mod=Moderate, Sev=Severe.

Table 1. Baseline Characteristics and Disease Severity by Endpoint

		Serology (N=47)	Psychological Survey (N=41) ¹
Sex	Women	28 (60%)	23 (56%)
	Men	19 (40%)	18 (44%)
Age	0-29	9 (19%)	7 (17%)
	30-59	25 (53%)	21 (51%)
	60+	13 (28%)	13 (32%)
Education Completed	Elementary School	11 (23%)	10 (24%)
	Middle/High School	15 (32%)	13 (32%)
	University or Higher	18 (38%)	18 (44%)
	Not Reported	3 (6%)	
Any Symptom Reported at the Time of Diagnosis	No	10 (21%)	8 (20%)
	Yes	37 (79%)	33 (80%)
Fever/History of Fever Reported at the Time of Diagnosis	No	25 (53%)	23 (56%)
	Yes	22 (47%)	18 (44%)
Comorbidity ²	No	32 (68%)	28 (68%)
	Yes	15 (32%)	13 (32%)
Disease Severity ³	Mild/Moderate	38 (81%)	33 (80%)
	Severe/Critical	9 (19%)	8 (20%)

Burc 8/27/20 1:32 PM
Formatted Table

Burc 9/27/20 1:02 PM
Comment [27]: To address question by Reviewer #1, this included chronic/recurring comorbidities, and hence, included seasonal allergies, but not acute infectious conditions such as common cold/flu. However, based on patient records, no specific acute infectious conditions/disease were noted.

676 ¹ Of the 47 individuals who provided blood samples for serology testing, four cases were
677 not invited to respond to the survey (one <18 years old, and three not fluent in local
678 language) and two declined to participate in the survey.
679 ² Most frequently reported chronic diseases were hypertension (N=9) and diabetes (N=5,
680 two with concurrent hypertension).

681 ³ Disease severity was defined as critical (requiring intensive care), severe (requiring
682 oxygen therapy, but otherwise stable) and mild/moderate (all other cases including
683 asymptomatic cases).
684

In review

Table 2. Descriptive Statistics and Correlations Between the Measured Psychological Processes

Process	M	SD	1	2	3	4	5	6	7	8
1. COVID-19 as Life-changing Trauma (CALCT)	3.17	1.41								
2. Negative Emotions	2.61	1.25	0.54**							
3. Perceived Discrimination	2.48	1.30	0.54**	0.24 ^{ns}						
4. Global Health before Diagnosis	4.45	0.72	-0.02 ^{ns}	-0.07 ^{ns}	0.09 ^{ns}					
5. Global Health after Diagnosis	4.21	0.83	-0.15 ^{ns}	-0.20 ^{ns}	-0.17 ^{ns}	0.42**				
6. Pro-social Tendencies	4.39	0.97	0.25 ^{ns}	0.28 ^{ns}	0.18 ^{ns}	-0.20 ^{ns}	-0.16 ^{ns}			
7. Perceived Importance of Protective Measures	4.42	1.00	0.24 ^{ns}	0.09 ^{ns}	0.09 ^{ns}	0.14 ^{ns}	-0.12 ^{ns}	0.41**		
8. Future Stigma Related Anxiety	1.99	1.06	0.54**	0.05 ^{ns}	0.80**	-0.07 ^{ns}	-0.06 ^{ns}	0.13 ^{ns}	-0.02 ^{ns}	

M=Mean, SD=Standard Deviation

Note. Standardized coefficients are shown. A psychological process score for a participant reflects the corresponding average score of the survey responses (in the ordinal scale of 1-5) used to measure that psychological process. Higher computed score indicated stronger experience of COVID-19 as a life changing trauma, perceived higher importance of preventive measures, stronger initial reaction to diagnosis, more positive evaluation of general health, more perceived discrimination, higher post-traumatic anxiety, or stronger anticipation of future COVID-19 related anxiety.

** p<0.001; ns: non-significant (p≥0.05).

Burc 10/3/20 7:28 PM

Comment [28]: Re-write

Burc 10/4/20 8:20 AM

Deleted: Scales went from 1 (strongly disagree) to 5 (strongly agree).

Figure 1.TIF




Figure 2.TIF

